Candel Therapeutics Analyst Ratings
Candel Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a maintained with a price target of $10.00 to $8.00. The current price Candel Therapeutics (CADL) is trading at is $1.67, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 379.04% | Credit Suisse | $10 → $8 | Maintains | Outperform |
| 12/02/2022 | 558.68% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 03/31/2022 | 618.56% | BMO Capital | $18 → $12 | Maintains | Outperform |
| 11/19/2021 | 977.84% | BMO Capital | → $18 | Initiates Coverage On | → Outperform |
| 08/23/2021 | 438.92% | UBS | → $9 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1217.37% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 08/23/2021 | 798.2% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/07/2022 | 379.04% | 瑞士信贷 | $10 → $8 | 维护 | 跑赢大盘 |
| 12/02/2022 | 558.68% | HC Wainwright公司 | → $11 | 开始承保 | →购买 |
| 03/31/2022 | 618.56% | 蒙特利尔银行资本 | $18 → $12 | 维护 | 跑赢大盘 |
| 11/19/2021 | 977.84% | 蒙特利尔银行资本 | → $18 | 开始承保 | →跑赢大盘 |
| 08/23/2021 | 438.92% | 瑞银集团 | → $9 | 开始承保 | →购买 |
| 08/23/2021 | 1217.37% | 杰富瑞 | → $22 | 开始承保 | →购买 |
| 08/23/2021 | 798.2% | 瑞士信贷 | → $15 | 开始承保 | →跑赢大盘 |
What is the target price for Candel Therapeutics (CADL)?
秋茄治疗公司(CADL)的目标价格是多少？
The latest price target for Candel Therapeutics (NASDAQ: CADL) was reported by Credit Suisse on December 7, 2022. The analyst firm set a price target for $8.00 expecting CADL to rise to within 12 months (a possible 379.04% upside). 3 analyst firms have reported ratings in the last year.
瑞士信贷于2022年12月7日报告了Candel治疗公司(纳斯达克：CADL)的最新目标价。这家分析公司将目标价定为8美元，预计CADL12个月内将升至(可能上涨379.04%)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Candel Therapeutics (CADL)?
Candel Treeutics(CADL)的最新分析师评级是什么？
The latest analyst rating for Candel Therapeutics (NASDAQ: CADL) was provided by Credit Suisse, and Candel Therapeutics maintained their outperform rating.
瑞信提供了对坎德尔治疗公司(纳斯达克代码：CADL)的最新分析师评级，坎德尔治疗公司维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Candel Treeutics(CADL)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Candel Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Candel治疗公司的上一次评级是在2022年12月7日提交的，所以你应该预计下一次评级将在2023年12月7日左右提供。
Is the Analyst Rating Candel Therapeutics (CADL) correct?
分析师对Candel Treeutics(CADL)的评级正确吗？
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a maintained with a price target of $10.00 to $8.00. The current price Candel Therapeutics (CADL) is trading at is $1.67, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Candel Treeutics(CADL)评级保持不变，目标价在10.00美元至8.00美元之间。秋茄治疗公司(CADL)目前的交易价格为1.67美元，超出了分析师的预测范围。
译文内容由第三方软件翻译。
